Gene network-based analysis identifies two potential subtypes of small intestinal neuroendocrine tumors

BMC Genomics

Volumn 15, Issue 1, 2014, Pages

  Kidd, Mark ^a   Modlin, Irvin M ^a   Drozdov, Ignat ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Bering Limited   (United Kingdom)

Author keywords

Blood; Gene marker; Microarray; Network; Neurodevelopment; Neuroendocrine tumor; qPCR; Secretome; Transcript

Indexed keywords

AMYLOID BETA PROTEIN; CARBOXYPEPTIDASE; CD59 ANTIGEN; PROPROTEIN CONVERTASE 1; SECRETOGRANIN II; SECRETOGRANIN V; SODIUM CHANNEL NAV1.3; TRANSCRIPTION FACTOR NKX2.2; TRANSCRIPTOME; ZINC FINGER PROTEIN; SEROTONIN; SUBSTANCE P; TRANSCRIPTION FACTOR;

AKT3 GENE; APLP1 GENE; APOPTOSIS; ARTICLE; BEX1 GENE; CANCER DIAGNOSIS; CANCER STEM CELL; CD59 GENE; CEBPA GENE; CELL PROLIFERATION; CLINICAL ARTICLE; CPE GENE; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC ANALYSIS; GLUCOSE HOMEOSTASIS; GPM6A GENE; HUMAN; HUMAN TISSUE; INSM1 GENE; MALE; NERVE CELL DIFFERENTIATION; NEUROD1 GENE; NEUROENDOCRINE TUMOR; NKX2 2 GENE; NUCLEOTIDE SEQUENCE; PCSK1 GENE; PCSK1N GENE; PCSK2 GENE; PHENOTYPE; PNMA2 GENE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY SEQUENCE; SCG2 GENE; SCG5 GENE; SCN3A GENE; SMALL INTESTINE NEUROENDOCRINE TUMOR; SMALL INTESTINE TUMOR; ST18 GENE; TAC1 GENE; TRANSCRIPTOMICS; TTR GENE; VALIDATION PROCESS; ADULT; AGED; DNA MICROARRAY; GENETICS; INTESTINE MUCOSA; INTESTINE TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROTEIN PROTEIN INTERACTION; SECRETION (PROCESS); VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE REGULATORY NETWORKS; HUMANS; INTESTINAL MUCOSA; INTESTINAL NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN INTERACTION MAPS; SEROTONIN; SUBSTANCE P; TRANSCRIPTION FACTORS; TRANSCRIPTOME;

EID: 84904083586     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-15-595     Document Type: Article

References (92)

1. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008, 9(1):61-72.
2. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011, 40(1):1-18. vii.
3. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, et al. One hundred years after " carcinoid" : epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008, 26(18):3063-3072.
4. Gustafsson BI, Siddique L, Chan A, Dong M, Drozdov I, Kidd M, Modlin IM. Uncommon cancers of the small intestine, appendix and colon: an analysis of SEER 1973-2004, and current diagnosis and therapy. Int J Oncol 2008, 33(6):1121-1131.
5. Schimmack S, Svejda B, Lawrence B, Kidd M, Modlin IM. The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch Surg 2011, 396(3):273-298.
6. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med 2003, 348(12):1134-1149.
7. Bauer MC, O'Connell DJ, Maj M, Wagner L, Cahill DJ, Linse S. Identification of a high-affinity network of secretagogin-binding proteins involved in vesicle secretion. Mol Biosyst 2011, 7(7):2196-2204. doi: 2110.1039/c2190mb00349b. Epub 02011 Apr 00328.
8. Park JJ, Gondre-Lewis MC, Eiden LE, Loh YP. A distinct trans-Golgi network subcompartment for sorting of synaptic and granule proteins in neurons and neuroendocrine cells. J Cell Sci 2011, 124(Pt 5):735-744. doi: 710.1242/jcs.076372.
9. Jakobsen AM, Andersson P, Saglik G, Andersson E, Kolby L, Erickson JD, Forssell-Aronsson E, Wangberg B, Ahlman H, Nilsson O. Differential expression of vesicular monoamine transporter (VMAT) 1 and 2 in gastrointestinal endocrine tumours. J Pathol 2001, 195(4):463-472.
10. Drozdov I, Svejda B, Gustafsson B, Mane S, Pfragner R, Kidd M, Modlin I. Gene Network Inference and Biochemical Assessment delineates GPCRPathways and CREB Targets in Small Intestinal Neuroendocrine Neoplasia. Plos One 2011, 6(8):e22457.
11. Christofi FL, Kim M, Wunderlich JE, Xue J, Suntres Z, Cardounel A, Javed NH, Yu JG, Grants I, Cooke HJ. Endogenous adenosine differentially modulates 5-hydroxytryptamine release from a human enterochromaffin cell model. Gastroenterology 2004, 127(1):188-202.
12. Bodei L, Kidd M, Modlin I, Paganelli G. Nuclear Medicine in the Diagnosis and Therapy of Neuroendocrine Tumors. Nuclear Oncology 2014, Wolters Kluwer Health, Akotlun C, Goldsmith S, in press.
13. Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, Papathanasiou ND, Pepe G, Oyen W, De Cristoforo C, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 2010, 37(10):2004-2010.
14. Zikusoka MN, Kidd M, Eick G, Latich I, Modlin IM. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer 2005, 104(11):2292-2309.
15. Zhao J, de Krijger RR, Meier D, Speel EJ, Saremaslani P, Muletta-Feurer S, Matter C, Roth J, Heitz PU, Komminoth P. Genomic alterations in well-differentiated gastrointestinal and bronchial neuroendocrine tumors (carcinoids): marked differences indicating diversity in molecular pathogenesis. Am J Pathol 2000, 157(5):1431-1438.
16. Kulke MH, Freed E, Chiang DY, Philips J, Zahrieh D, Glickman JN, Shivdasani RA. High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss. Genes Chromosomes Cancer 2008, 47(7):591-603. doi: 510.1002/gcc.20561.
17. Kytola S, Hoog A, Nord B, Cedermark B, Frisk T, Larsson C, Kjellman M. Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids. Am J Pathol 2001, 158(5):1803-1808.
18. Lollgen RM, Hessman O, Szabo E, Westin G, Akerstrom G. Chromosome 18 deletions are common events in classical midgut carcinoid tumors. Int J Cancer 2001, 92(6):812-815.
19. Banck MS, Kanwar R, Kulkarni AA, Boora GK, Metge F, Kipp BR, Zhang L, Thorland EC, Minn KT, Tentu R, et al. The genomic landscape of small intestine neuroendocrine tumors. J Clin Invest 2013, 15:67963.
20. Kidd M, Modlin IM, Mane SM, Camp RL, Eick G, Latich I. The role of genetic markers--NAP1L1, MAGE-D2, and MTA1--in defining small-intestinal carcinoid neoplasia. Ann Surg Oncol 2006, 13(2):253-262. Epub 2006 Jan 2020.
21. Leja J, Essaghir A, Essand M, Wester K, Oberg K, Totterman TH, Lloyd R, Vasmatzis G, Demoulin JB, Giandomenico V. Mod Pathol 2009, 22(2):261-272. Epub 2008 Oct 2024.
22. Edfeldt K, Bjorklund P, Akerstrom G, Westin G, Hellman P, Stalberg P. Different gene expression profiles in metastasizing midgut carcinoid tumors. Endocr Relat Cancer 2011, 18(4):479-489. Print 2011 Aug.
23. Posorski N, Kaemmerer D, Ernst G, Grabowski P, Hoersch D, Hommann M, von Eggeling F. Localization of sporadic neuroendocrine tumors by gene expression analysis of their metastases. Clin Exp Metastasis 2011, 28(7):637-647. doi: 610.1007/s10585-10011-19397-10585. Epub 12011 Jun 10517.
24. van 'tVeer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415(6871):530-536.
25. Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, Bild A, Iversen ES, Liao M, Chen CM, et al. Gene expression predictors of breast cancer outcomes. Lancet 2003, 361(9369):1590-1596.
26. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006, 24(26):4236-4244.
27. Cheng SH, Horng CF, West M, Huang E, Pittman J, Tsou MH, Dressman H, Chen CM, Tsai SY, Jian JJ, et al. Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol 2006, 24(28):4594-4602.
28. Helland A, Johnsen H, Froyland C, Landmark HB, Saetersdal AB, Holmen MM, Gjertsen T, Nesland JM, Ottestad W, Jeffrey SS, et al. Radiation-induced effects on gene expression: an in vivo study on breast cancer. Radiother Oncol 2006, 80(2):230-235.
29. Zander T, Hofmann A, Staratschek-Jox A, Classen S, Debey-Pascher S, Maisel D, Ansen S, Hahn M, Beyer M, Thomas RK, et al. Blood-based gene expression signatures in non-small cell lung cancer. Clin Cancer Res 2011, 17(10):3360-3367.
30. Yates DR, Roupret M, Drouin SJ, Comperat E, Ricci S, Lacave R, Sebe P, Cancel-Tassin G, Bitker MO, Cussenot O. Quantitative RT-PCR analysis of PSA and prostate-specific membrane antigen mRNA to detect circulating tumor cells improves recurrence-free survival nomogram prediction after radical prostatectomy. Prostate 2012, 6(10):22488.
31. Mead R, Duku M, Bhandari P, Cree IA. Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer 2011, 105(2):239-245. doi: 210.1038/bjc.2011.1230. Epub 2011 Jun 1028.
32. Della Gatta G, Palomero T, Perez-Garcia A, Ambesi-Impiombato A, Bansal M, Carpenter ZW, De Keersmaecker K, Sole X, Xu L, Paietta E, et al. Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL. Nat Med 2012, 18(3):436-440. doi:410.1038/nm.2610.
33. Schreiber SL, Shamji AF, Clemons PA, Hon C, Koehler AN, Munoz B, Palmer M, Stern AM, Wagner BK, Powers S, et al. Towards patient-based cancer therapeutics. Nat Biotechnol 2010, 28(9):904-906.
34. Drozdov I, Bornschein J, Wex T, Valeyev NV, Tsoka S, Malfertheiner P. Functional and topological properties in hepatocellular carcinoma transcriptome. PLoS One 2012, 7(4):e35510. Epub 32012 Apr 35523.
35. Drozdov I, Ouzounis CA, Shah AM, Tsoka S. Functional Genomics Assistant (FUGA): a toolbox for the analysis of complex biological networks. BMC Res Notes 2011, 4(1):462.
36. Drozdov I, Tsoka S, Ouzounis CA, Shah AM. Genome-wide expression patterns in physiological cardiac hypertrophy. BMC Genomics 2010, 11:557.
37. Shepherd R, Forbes SA, Beare D, Bamford S, Cole CG, Ward S, Bindal N, Gunasekaran P, Jia M, Kok CY, et al. Data mining using the Catalogue of Somatic Mutations in Cancer BioMart. Database (Oxford) 2011, 2011:bar018. (doi):10.1093/database/bar1018. Print 2011.
38. Habib AM, Richards P, Cairns LS, Rogers GJ, Bannon CA, Parker HE, Morley TC, Yeo GS, Reimann F, Gribble FM. Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology 2012, 153(7):3054-3065. doi: 3010.1210/en.2011-2170. Epub 2012 Jun 3058.
39. Baysal BE. Mitochondrial complex II and genomic imprinting in inheritance of paraganglioma tumors. Biochim Biophys Acta 2013, 1827(5):573-577. doi: 510.1016/j.bbabio.2012.1012.1005. Epub 2013 Jan 1012.
40. Alberich-Jorda M, Wouters B, Balastik M, Shapiro-Koss C, Zhang H, Di Ruscio A, Radomska HS, Ebralidze AK, Amabile G, Ye M, et al. C/EBPgamma deregulation results in differentiation arrest in acute myeloid leukemia. J Clin Invest 2012, 122(12):4490-4504. doi: 4410.1172/JCI65102. Epub 62012 Nov 65119.
41. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487(7407):330-337. doi: 310.1038/nature11252.
42. Huegel J, Sgariglia F, Enomoto-Iwamoto M, Koyama E, Dormans JP, Pacifici M. Heparan sulfate in skeletal development, growth, and pathology: the case of hereditary multiple exostoses. Dev Dyn 2013, 242(9):1021-1032. doi: 1010.1002/dvdy.24010. Epub 22013 Jul 24029.
43. Merkel AL, Meggers E, Ocker M. PIM1 kinase as a target for cancer therapy. Expert Opin Investig Drugs 2012, 21(4):425-436. doi: 410.1517/13543784.13542012.13668527. Epub 13542012 Mar 13543784.
44. Mardis ER, Wilson RK. Cancer genome sequencing: a review. Human molecular genetics 2009, 18(R2):R163-R168.
45. Makridis C, Theodorsson E, Akerstrom G, Oberg K, Knutson L. Increased intestinal non-substance P tachykinin concentrations in malignant midgut carcinoid disease. J Gastroenterol Hepatol 1999, 14(5):500-507.
46. Calhoun K, Toth-Fejel S, Cheek J, Pommier R. Serum peptide profiles in patients with carcinoid tumors. Am J Surg 2003, 186(1):28-31.
47. La Rosa S, Franzi F, Albarello L, Schmitt A, Bernasconi B, Tibiletti MG, Finzi G, Placidi C, Perren A, Capella C. Serotonin-producing enterochromaffin cell tumors of the pancreas: clinicopathologic study of 15 cases and comparison with intestinal enterochromaffin cell tumors. Pancreas 2011, 40(6):883-895. doi: 810.1097/MPA.1090b1013e31822041a31822049.
48. Cui T, Hurtig M, Elgue G, Li SC, Veronesi G, Essaghir A, Demoulin JB, Pelosi G, Alimohammadi M, Oberg K, et al. Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors. PLoS One 2010, 5(12):e16010.
49. Arvidsson Y, Andersson E, Bergstrom A, Andersson MK, Altiparmak G, Illerskog AC, Ahlman H, Lamazhapova D, Nilsson O. Amyloid precursor-like protein 1 is differentially upregulated in neuroendocrine tumours of the gastrointestinal tract. Endocr Relat Cancer 2008, 15(2):569-581. doi:510.1677/ERC-1607-0145. Epub 2008 Apr 1622.
50. Gagnon J, Mayne J, Mbikay M, Woulfe J, Chretien M. Expression of PCSK1 (PC1/3), PCSK2 (PC2) and PCSK3 (furin) in mouse small intestine. Regul Pept 2009, 152(1-3):54-60. doi:10.1016/j.regpep.2008.1007.1006. Epub 2008 Jul 1022.
51. Thimmapaya R, Neelands T, Niforatos W, Davis-Taber RA, Choi W, Putman CB, Kroeger PE, Packer J, Gopalakrishnan M, Faltynek CR, et al. Distribution and functional characterization of human Nav1.3 splice variants. Eur J Neurosci 2005, 22(1):1-9.
52. Kidd M, Modlin IM, Gustafsson BI, Drozdov I, Hauso O, Pfragner R. Luminal regulation of normal and neoplastic human EC cell serotonin release is mediated by bile salts, amines, tastants, and olfactants. Am J Physiol Gastrointest Liver Physiol 2008, 295(2):G260-G272.
53. Hains BC, Klein JP, Saab CY, Craner MJ, Black JA, Waxman SG. Upregulation of sodium channel Nav1.3 and functional involvement in neuronal hyperexcitability associated with central neuropathic pain after spinal cord injury. J Neurosci 2003, 23(26):8881-8892.
54. Jandrig B, Seitz S, Hinzmann B, Arnold W, Micheel B, Koelble K, Siebert R, Schwartz A, Ruecker K, Schlag PM, et al. ST18 is a breast cancer tumor suppressor gene at human chromosome 8q11.2. Oncogene 2004, 23(57):9295-9302.
55. Yang J, Siqueira MF, Behl Y, Alikhani M, Graves DT. The transcription factor ST18 regulates proapoptotic and proinflammatory gene expression in fibroblasts. Faseb J 2008, 22(11):3956-3967. doi:3910.1096/fj.3908-111013. Epub 112008 Aug 111011.
56. Kameyama T, Matsushita F, Kadokawa Y, Marunouchi T. Myt/NZF family transcription factors regulate neuronal differentiation of P19 cells. Neurosci Lett 2011, 497(2):74-79. doi:10.1016/j.neulet.2011.1004.1033. Epub 2011 Apr 1022.
57. Wang S, Zhang J, Zhao A, Hipkens S, Magnuson MA, Gu G. Loss of Myt1 function partially compromises endocrine islet cell differentiation and pancreatic physiological function in the mouse. Mech Dev 2007, 124(11-12):898-910. Epub 2007 Sep 2004.
58. Khazaei MR, Halfter H, Karimzadeh F, Koo JH, Margolis FL, Young P. Bex1 is involved in the regeneration of axons after injury. J Neurochem 2010, 115(4):910-920. doi:910.1111/j.1471-4159.2010.06960.x. Epub 02010 Sep 06928.
59. Hofsli E, Wheeler TE, Langaas M, Laegreid A, Thommesen L. Identification of novel neuroendocrine-specific tumour genes. Br J Cancer 2008, 99(8):1330-1339. doi:1310.1038/sj.bjc.6604565. Epub 6602008 Sep 6604530.
60. Ruau D, Ensenat-Waser R, Dinger TC, Vallabhapurapu DS, Rolletschek A, Hacker C, Hieronymus T, Wobus AM, Muller AM, Zenke M. Pluripotency associated genes are reactivated by chromatin-modifying agents in neurosphere cells. Stem Cells 2008, 26(4):920-926. doi:910.1634/stemcells.2007-0649. Epub 2008 Jan 1617.
61. Borczuk AC, Gorenstein L, Walter KL, Assaad AA, Wang L, Powell CA. Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol 2003, 163(5):1949-1960.
62. Kalari S, Jung M, Kernstine KH, Takahashi T, Pfeifer GP. The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells. Oncogene 2012, 20(10):362.
63. Rosenbaum JN, Duggan A, Garcia-Anoveros J. Insm1 promotes the transition of olfactory progenitors from apical and proliferative to basal, terminally dividing and neuronogenic. Neural Dev 2011, 6:6. (doi):10.1186/1749-8104-1186-1186.
64. Horb LD, Jarkji ZH, Horb ME. Xenopus insm1 is essential for gastrointestinal and pancreatic endocrine cell development. Dev Dyn 2009, 238(10):2505-2510. doi:2510.1002/dvdy.22071.
65. Zhang T, Liu WD, Saunee NA, Breslin MB, Lan MS. Zinc finger transcription factor INSM1 interrupts cyclin D1 and CDK4 binding and induces cell cycle arrest. J Biol Chem 2009, 284(9):5574-5581. doi:5510.1074/jbc.M808843200. Epub 808842009 Jan 808843205.
66. Zhang T, Saunee NA, Breslin MB, Song K, Lan MS. Functional role of an islet transcription factor, INSM1/IA-1, on pancreatic acinar cell trans-differentiation. J Cell Physiol 2012, 227(6):2470-2479. doi:2410.1002/jcp.22982.
67. Desai S, Loomis Z, Pugh-Bernard A, Schrunk J, Doyle MJ, Minic A, McCoy E, Sussel L. Nkx2.2 regulates cell fate choice in the enteroendocrine cell lineages of the intestine. Dev Biol 2008, 313(1):58-66. Epub 2007 Oct 2003.
68. Kordowich S, Collombat P, Mansouri A, Serup P. Arx and Nkx2.2 compound deficiency redirects pancreatic alpha- and beta-cell differentiation to a somatostatin/ghrelin co-expressing cell lineage. BMC Dev Biol 2011, 11:52. doi:10.1186/1471-1213X-1111-1152.
69. Papizan JB, Singer RA, Tschen SI, Dhawan S, Friel JM, Hipkens SB, Magnuson MA, Bhushan A, Sussel L. Nkx2.2 repressor complex regulates islet beta-cell specification and prevents beta-to-alpha-cell reprogramming. Genes Dev 2011, 25(21):2291-2305. doi: 2210.1101/gad.173039.173111.
70. Liu W, Enwright JF, Hyun W, Day RN, Schaufele F. CCAAT/enhancer binding protein alpha uses distinct domains to prolong pituitary cells in the growth 1 and DNA synthesis phases of the cell cycle. BMC Cell Biol 2002, 3:6.
71. Keeshan K, Santilli G, Corradini F, Perrotti D, Calabretta B. Transcription activation function of C/EBPalpha is required for induction of granulocytic differentiation. Blood 2003, 102(4):1267-1275. Epub 2003 Apr 1217.
72. von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, Wiedenmann B, Boehm BO, Adler G, Seufferlein T. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 2000, 60(16):4573-4581.
73. Zhou Y, Wang S, Yue BG, Gobl A, Oberg K. Effects of interferon alpha on the expression of p21cip1/waf1 and cell cycle distribution in carcinoid tumors. Cancer Invest 2002, 20(3):348-356.
74. Hoekstra AS, Bayley JP. The role of complex II in disease. Biochim Biophys Acta 2013, 1827(5):543-551. doi:510.1016/j.bbabio.2012.1011.1005. Epub 2012 Nov 1020.
75. Perren A, Barghorn A, Schmid S, Saremaslani P, Roth J, Heitz PU, Komminoth P. Absence of somatic SDHD mutations in sporadic neuroendocrine tumors and detection of two germline variants in paraganglioma patients. Oncogene 2002, 21(49):7605-7608.
76. Katona TM, Jones TD, Wang M, Abdul-Karim FW, Cummings OW, Cheng L. Molecular evidence for independent origin of multifocal neuroendocrine tumors of the enteropancreatic axis. Cancer Res 2006, 66(9):4936-4942.
77. Drozdov I, Kidd M, Nadler B, Camp RL, Mane SM, Hauso O, Gustafsson BI, Modlin IM. Predicting neuroendocrine tumor (carcinoid) neoplasia using gene expression profiling and supervised machine learning. Cancer 2009, 115(8):1638-1650.
78. Modlin IM, Gustafsson BI, Drozdov I, Nadler B, Pfragner R, Kidd M. Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors. Ann Surg Oncol 2009, 16(2):487-498.
79. Modlin I, Drozdov I, Kidd M. The Identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. Plos One 2013, 8(5):e63364.
80. McClintick JN, Edenberg HJ. Effects of filtering by Present call on analysis of microarray experiments. BMC Bioinformatics 2006, 7:49.
81. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003, 31(4):e15.
82. Kauffmann A, Gentleman R. Huber W: arrayQualityMetrics-a bioconductor package for quality assessment of microarray data. Bioinformatics 2009, 25(3):415-416.
83. Maglott D, Ostell J, Pruitt KD, Tatusova T. Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res 2011, 39(Database issue):D52-D57.
84. Boulesteix AL, Slawski M. Stability and aggregation of ranked gene lists. Briefings in bioinformatics 2009, 10(5):556-568.
85. Alexa A, Rahnenfuhrer J, Lengauer T. Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. Bioinformatics 2006, 22(13):1600-1607.
86. Croft D, O'Kelly G, Wu G, Haw R, Gillespie M, Matthews L, Caudy M, Garapati P, Gopinath G, Jassal B, et al. Reactome: a database of reactions, pathways and biological processes. Nucleic acids research 2011, 39(Database issue):D691-D697.
87. Bauer S, Robinson PN, Gagneur J. Model-based gene set analysis for Bioconductor. Bioinformatics 2011, 27(13):1882-1883.
88. Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, Tyers M. BioGRID: a general repository for interaction datasets. Nucleic Acids Res 2006, 34(Database issue):D535-D539.
89. Clauset A, Newman MEJ, Moore C. Finding community structure in very large networks. Phys Rev E 2004, 70(6):066111.
90. Kidd M, Eick G, Shapiro MD, Camp RL, Mane SM, Modlin IM. Microsatellite instability and gene mutations in transforming growth factor-beta type II receptor are absent in small bowel carcinoid tumors. Cancer 2005, 103(2):229-236.
91. Kidd M, Nadler B, Mane S, Eick G, Malfertheiner M, Champaneria M, Pfragner R, Modlin I. GeneChip, geNorm, and gastrointestinal tumors: novel reference genes for real-time PCR. Physiol Genomics 2007, 30(3):363-370.
92. Dalman MR, Deeter A, Nimishakavi G, Duan ZH. Fold change and p-value cutoffs significantly alter microarray interpretations. BMC Bioinformatics 2012, 13(Suppl 2):S11.